VRDN Company Profile and Key Details

Viridian Therapeutics, Inc. (NASDAQ:VRDN) closed at $28.62 USD, losing -$0.57 (-1.95%) from the previous close of $29.19. The stock is currently mid-range between its 52-week high and low $9.90 and $34.29. With a market capitalization of about $2.43 billion, Viridian Therapeutics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.01). Key stats such as the average daily volume over the past year has been around 1.45 million shares, in line with its 52-week average. Headquartered in Waltham, MA, Viridian Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Stephen F. Mahoney, the company employs approximately 143 people and listed since June 18, 2014. Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases.

Viridian Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$11.58. This means the shares are trading below this model’s fair value.

Short-term trend indicators are mixed aligned (SMA20 -0.82%, SMA50 -5.34%, SMA200 29.14%). The stock’s 14-day RSI is 47.3 (neutral), while the ATR of 1.53 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -14.0% below its high and over 197.88% above its low. Average 10-day trading volume of 1.12 million shares is below the 3-month average of 1.37 million, indicating normal recent market interest.

Viridian Therapeutics, Inc. generated EPS of -$3.53 over the past year. Five-year average earnings growth is 31.28%. Wall Street analysts project EPS growth of 24.01% annually over the next five years. The latest quarter delivered EPS of -$0.42. The next quarter is forecast at -$0.98. Next year's EPS is expected at $13.21. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 9 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $61.00 to $26.00. The high target offers 113.14% upside. The low target suggests -9.15% downside. The mean target is $40.37. This offers 41.06% upside. Viridian Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -54.99%. The prior quarter beat by 2.23%. Over the last six quarters, Apple has recorded several small beats. These include 17.24% in August 08, 2024.

Viridian Therapeutics, Inc. has 81.66 million shares outstanding. The public float is 66.94 million shares, elevated short interest at 14.80% of float. This equals 11.57 million shares. The short ratio is 13.77 days. Institutional investors hold 101.47% of the float. Insiders own 0.14%. Fairmount Funds Management LLC holds 3.91 million shares, Frazier Life Sciences Public Fund, L.P. has 1.51 million shares and Fairmount Healthcare Fund II L.P. has 1.36 million shares. Over the past six months, insider transactions show balanced activity. They sold 2.27 thousand shares across 1 transactions.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) shares are flat 4.88% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Viridian Therapeutics, Inc. trading at a premium to the broader market with a P/E of -7.05. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $38.76, suggesting 35.43% upside. Our AI forecast model points to short-term strength (2.17% over two weeks), a medium-term fall (-7.55% over three months), and a longer-term gain (12.26% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Viridian Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.17%, with price expected at $29.24 by March 24, 2026, within a range of $28.05 to $30.37 3-Month Outlook: Projected fall of -7.55%, reaching $26.46 by June 08, 2026, with a range of $25.09 to $27.67. 1-Year Outlook: Projected gain of 12.26%, with price at $32.13 by March 10, 2027, within a range of $29.53 to $34.01.

Viridian Therapeutics, Inc. trades at a P/E ratio of -7.05, slightly below the S&P 500 average, with a price-to-sales ratio of 34.11 and a price-to-book ratio of 3.34 trading at moderately above to book value. The P/FCF stands at -8.73, also below market averages.